Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana

Journal of the International Association of Physicians in AIDS Care

Volumn 11, Issue 4, 2012, Pages 260-268

  Tolle, Michael ^a,b,c   Howard, Leigh ^a,b   Kirk, Brianna ^a,b   Gomila, Andres ^a,b   Schwarzwald, Heidi ^b,c   Anabwani, Gabriel ^a,b,c  

^a Princess Marina Hospital   (Botswana)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Botswana; HIV 1 subtype C; pediatric antiretroviral therapy; reverse transcriptase genotypes; reverse transcriptase resistance mutations

Indexed keywords

EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

BOTSWANA; CHILD; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD;

ANTI-HIV AGENTS; BENZOXAZINES; BOTSWANA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; MUTATION; NEVIRAPINE; PYRIDAZINES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; STAVUDINE; THYMIDINE; TREATMENT FAILURE; ZIDOVUDINE;

EID: 84865098815     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109711422273     Document Type: Review

References (46)

1. Data, Botswana National HIV Prevalence Survey. Botswana: Ministry of Health ; 2009 :
2. Data, Botswana National PMTCT Program (NACA). Botswana: Ministry of Health ; 2010:
3. Sohn AH, Ananworanich J. HAART for children with treatment failure. HIV Ther. 2009 ; 3 (5). 485-499
4. Ferreira FG, Pinto JA, Kakehasi FM, et al. Prevalence of primary drug resistance-associated mutations among HIV type 1 vertically infected children in Belo Horizonte, Brazil. AIDS Res Hum Retroviruses. 2010 ; 26 (2). 229-232
5. Almeida FJ, Berezin EN, Rodrigues R, et al. Diversity and prevalence of antiretroviral genotypic resistance mutations among HIV-1 infected children. J Pediatr (Rio J). 2009 ; 85 (2). 104-109
6. Dumans AT, Barreto CC, Santos AF, et al. Distinct resistance mutations and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure. Infect Genet Evol. 2009 ; 9 (1). 62-70
7. Brindero PA, Brindero RM, Mortensen C, et al. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol. 2002 ; 40 (12). 4512-4519 (Pubitemid 35434939)
8. Mullen J, Leech S, O'Shea S, et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol. 2002 ; 68 (3). 299-304
9. Wilkinson E, Engelbrecht S. Molecular characterization of non-subtype C and recombinant HIV-1 viruses from Cape Town, South Africa. Infect Genet Evol. 2009 ; 9 (5). 840-846
10. Ministry of Health. Botswana Second Generation HIV Antenatal Sentinel Surveillance Technical Report. Botswana: Ministry of Health; 2009. http://www.hiv.gov.bw/uploads/2009ancss.pdf. Accessed August 1, 2011.
11. Novitsky V, Wester CW, DeGruttola V, et al. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses. 2007 ; 23 (7). 868-878 (Pubitemid 47267493)
12. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc. 2009 ; 12 (1). 11
13. Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 ; 24 (11). 1449-1454
14. Wallis CL, Erasmus L, Varughese S, Ndiweni D, Stevens WS. Emergence of drug resistance in HIV-1 subtype C infected children failing the South Africa national antiretroviral rollout program. Pediatr Infect Dis J. 2009 ; 28 (12). 1123-1125
15. Wallis CL, Mellors JW, Venter WDF, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 ; 53 (4). 480-484
16. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008 ; 46: 1589-1597 (Pubitemid 351706742)
17. Maldonado F, Biot M, Roman F, et al. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. Trans R Soc Trop Med Hyg. 2009 ; 103 (6). 607-612
18. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naïve patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther. 2009 ; 14 (4). 523-531
19. Turner D, Shahar E, Katchman E, et al. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel. J Med Virol. 2009 ; 81 (9). 1509-1512
20. Hosseinepour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS. 2009 ; 23 (9). 1127-1134
21. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother. 2006 ; 50 (12). 4182-4185 (Pubitemid 44865165)
22. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a Public Health Approach, 2010 Revision. Geneva, Switzerland: World Health Organization. http://whqlibdoc.who.int/publications/2010/9789241599801-eng.pdf. Accessed May 17, 2011.
23. Lesotho National ART Guidelines. Maseru, Lesotho: Ministry of Health and Social Welfare ; 2009:
24. National Department of Health, South Africa. Guidelines for the Management of HIV in Children. 2nd ed. Pretoria, South Africa: National Department of Health; 2010. http://www.sanac.org.za/documents/ 2010%20Paediatric%20Guidelines.pdf. Accessed May 17, 2011.
25. Department of HIV/AIDS Prevention and Care, Ministry of Health. BotswanaNational HIV/AIDS Treatment Guidelines, 2008 Version. Gaborone, Botswana: Department of HIV/AIDS Prevention and Care, Ministry of Health; 2008. http://www.moh.gov.bw/templates/moh/File/ BOTSWANA%20HIVAIDS%20TREATMENT%20%20GUIDELINES%20(November%201%202008).pdf. Accessed May 17, 2011.
26. Kirk B, Howard L, Tolle M, Gomila A, Mabikwa V, Anabwani G
27. Stanford University. HIV Drug Resistance Database Web site. http:hivdb.stanford.edu/. Accessed July 25, 2010.
28. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-2: 24 week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 ; 370 (9581). 39-48 (Pubitemid 47017467)
29. Madruga JV, Cahn P, Grinsztein B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24 week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007 ; 370 (9581). 29-38 (Pubitemid 47017466)
30. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003 ; 17 (1). F1 - F5
31. Sohn AH, Nuttall JJ, Zhang F. Sequencing of antiretroviral therapy in children in low- and middle-income countries. Curr Opin HIV AIDS. 2010 ; 5 (1). 54-60
32. Kekitinwa A, Friedman D, Coakley E, et al. Profiling etravirine resistance in Ugandan children with extended failure of a NNRTI-inclusive regimen as first line ART.:
33. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. Curr HIV Res. 2008 ; 6 (5). 474-476
34. Cordova E, Loiza E, Porteiro N, Mingrone H. Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina. Enferm Infecc Microbiol Clin. 2011 ; 29 (6). 428-431
35. Kiertiburanakul S, Wiboonchutikul S, Sukasem C, Chantratita W, Sungkanuparph S. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. J Clin Virol. 2010 ; 47: 330-334
36. Taiwo B, Chaplin B, Penugonda S, et al. Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr HIV Res. 2010 ; 8 (3). 194-198
37. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C and D. J Acquir Immune Defic Syndr. 2006 ; 42 (5). 610-613 (Pubitemid 44162432)
38. Miller MD, Margot N, McColl D, Cheng AK. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. AIDS. 2007 ; 21 (2). 265-266 (Pubitemid 46036948)
39. Coustinos D, Invernizzi CF, Xu H, Brenner BG, Wainberg MA. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother. 2010 ; 20 (3). 117-131
40. Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther. 2009 ; 3 (6). 583-594
41. von Wyl V, Yerly S, Böni J, et al. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis. 2008 ; 46 (8). 1299-1309 (Pubitemid 351589918)
42. Deshpande A, Jeannot AC, Schrive MH, Wittkop L, Pinson P, Fleury HJ. Analysis of RT sequences of subtype C HIV-type 1 isolates from Indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines. AIDS Res Hum Retroviruses. 2010 ; 26 (3). 343-350
43. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. 2010 Revision. Geneva, Switzerland: World Health Organization ; 2010:
44. Li JF, Lipscomb JT, Wei X, et al. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naïve chronic and acute HIV-1 subtype C infections. J Infect Dis. 2011 ; 203 (6). 798-802
45. Feng JY, Myrick FT, Margot NA, et al. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine. Nucleosides Nucleotides Nucleic Acids. 2006 ; 25 (1). 89-107
46. Turner D, Brenner BG, Routy JP, Petrella M, Wainberg MA. Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment-experienced patients. New Microbiol. 2004 ; 27 (2 suppl 1). 31-39 (Pubitemid 40090987)